Publications scientifiques

Depuis le 23/02/2026
  1. SGLT-2 Inhibitors Use in Hospitalized Patients in France: A Cross-Sectional Study.
    Demourgues M, Bezin J, Griffier R, Pariente A, Noize P, de Germay S.
    Fundam Clin Pharmacol. 2026
  2. Impact of secured prescription implementation on ambulatory pregabalin use in France: A regional assessment in the French Nouvelle-Aquitaine.
    Munech-Herran M, Moysan V, Lescarret B, Mathieu C, Pariente A, Rousselot N.
    Br J Clin Pharmacol. 2026
  3. Language models in pharmacovigilance: Applications, promises and limits.
    Salvo F, Crupi L, Cholle C.
    Therapie. 2026
  4. Coprescription of antipsychotics and benzodiazepines at hospital discharge.
    Demourgues M, Richaud A, Thiec J, Debruyne AL, Guillemin S, Tournier M, Salvo F, Queuille E.
    Encephale. 2026
  5. Drugs associated with generalized non-allergic pruritus: A World Health Organization pharmacovigilance database analysis.
    Kondor L, Cicala G, Salvo F, Clabecq C, Misery L, Brenaut E, Gourier G, Le Garrec R.
    J Am Acad Dermatol. 2026
  6. Hepatobiliary adverse drug reactions during treatment with olaparib: an analysis of data from the EudraVigilance reporting system.
    Velişcu EM, Cagnotta C, Sullo MG, Anatriello A, Salvo F, Scavone C.
    Front Drug Saf Regul. 2026
  7. How can the level of health product education (literacy) be raised among the general public?
    Locher C, Manaud N, Molimard M, Cassé-Perrot C, Cracowski JL, Di Palma C, Duchossoy L, Gatignol C, Goldgewicht A, Hertel O, Lacombe K, Lacroix C, Moreau-Chevrolet P, Quelet S, Rivière P, Lagouanelle MC, Micallef J.
    Therapie. 2026
  8. Standardizing and Comparing Management Recommendations for Potential Drug-Drug Interactions Across Different Interaction Checkers.
    Crupi L, Letinier L, Jouhet V, Cossin S, Pariente A, Mathieu C, Martin GL, Konschelle F, Rouanet J, Carollo M, Trifirò G, Esposito E, Salvo F.
    Drug Saf. 2026
  9. How to differentiate between clinical added value (CAV) V drugs: What are the implications, and what is the access pathway?
    Body C, Chassagnol F, Berdaï D, Bergmann JF, Borget I, Doré C, Durr A, Falissard B, Hudry J, Kowalski B, Maugendre P, Schlumberger N, Wilmet É, Le Jeunne C.
    Therapie. 2026
  10. How to differentiate between clinical added value (CAV) V drugs: What are the implications, and what is the access pathway?
    Body C, Chassagnol F, Berdaï D, Bergmann JF, Borget I, Doré C, Durr A, Falissard B, Hudry J, Kowalski B, Maugendre P, Schlumberger N, Wilmet E, Le Jeunne C.
    Therapie. 2025
  11. Impact of Regulatory Events on JAK Inhibitor Prescribing in Rheumatoid Arthritis: Insights from the French MAJIK Registry.
    Truchetet ME, Prati C, Thevenot P, Bologna C, Alegria GC, Daien CI, Cornec D, Dernis E, Fautrel B, Pariente A, Roux C, Salmon JH, Sellam J, Hucteau E, Bezin J, Avouac J.
    Joint Bone Spine. 2025
  12. The Rising Misuse of Pharmacovigilance Reporting Systems: A Threat to Evidence-Based Medicine.
    Khouri C, Hlavaty A, Fusaroli M, Joshi N, Salvo F, Bate A, Pariente A, Raschi E.
    Clin Pharmacol Ther. 2026
  13. Clinical and toxicological epidemiology of intoxications by new psychoactive substances in Reunion Island.
    Maillot A, Guyon J, Ma-Tsi-Leong M, Berly L, Weisse F, Mahé A, Roux GL, Nativel F, Daveluy A, Puech B, Marteau A, Leroy M, Plé O, Maillard O, Bastard S, Mete D.
    Int J Emerg Med. 2025
  14. Effectiveness of antihypertensive drugs for secondary prevention of ischaemic stroke: a nationwide historic cohort study.
    Perrier J, Gabet A, Olié V, Pariente A, Tzourio C, Bezin J.
    BMJ Open. 2025
  15. Impact of Liquid Sublingual Immunotherapy on Health Care Resource Use in Allergic Rhinitis and Asthma in the Real-world EfficAPSI Study.
    Devillier P, Demoly P, Bergmann JF, Delaisi B, Gouverneur A, Vadel J, Collin C, Girard L, Scurati S, Molimard M.
    J Investig Allergol Clin Immunol. 2025
  16. Angiogenesis Inhibitors and Arterial Dissection or Aneurysm in Patients With Metastatic Colorectal Cancer.
    Singier A, Jarne Munoz A, Maumus-Robert S, Bérard X, Pariente A, Bezin J, Kempf E, Noize P.
    JAMA Netw Open. 2025
  17. Moving towards COPD control: Lessons, challenges, and the role of CONDOR, a new French respiratory research network.
    Ribeiro-Baptista B, Girodet PO, Le Rouzic O, Zysman M, Roche N, Regard L.
    Respir Med Res. 2025
  18. Sex Differences in the Use and Discontinuation of Recommended Drugs in Secondary Ischemic Stroke Prevention: A Regional Registry-Based Analysis.
    Perrier J, Domecq S, Lesaine E, Gilbert F, Saillour-Glenisson F, Rouanet F, Bezin J.
    J Womens Health (Larchmt). 2025
  19. How synthetic cannabinoid user profiles and consumption patterns can affect wastewater-based epidemiology.
    Devault DA, Peyré A, Cottereau V, Pleignet E, Daveluy A.
    Environ Sci Pollut Res Int. 2025
  20. Pharmacoepidemiology as the delicate science of constructing robust plausibility where there is no certainty: the case for hypertension in young adults.
    Pariente A.
    Eur Heart J. 2025